MDAI Stock Forecast & Price Target

Spectral AI is supported by a meaningful FDA clearance for its DeepView System, validating years of development and opening the door to a planned commercial launch in 2H26 across burn centers, trauma centers, and emergency departments. Its investment case is strengthened by BARDA backing, including about $31.7M in funding, expected distribution of roughly 30 systems, and a contract that could subsidize up to about 140 additional systems, reducing adoption risk and supporting early revenue. Fundamentally, the company addresses a large under-penetrated market with an estimated $3.7B TAM, and analysts project FY26 revenue of $18.5M with 110% CAGR through FY30, aided by a recurring high-margin license model and international upside.

Spectral AI is viewed negatively because its revenue outlook is highly dependent on BARDA-related funding, and any longer clinical or regulatory development timelines would directly reduce expected revenue. The company also faces meaningful execution risk from potential setbacks in regulatory or commercial approvals that could require additional analysis, filings, or clinical data, while weaker commercial uptake of DeepView would limit adoption. More broadly, limited awareness of the technology, a short operating history, competition, limited reimbursement, cybersecurity risk, and the possible need for additional capital all heighten fundamental uncertainty.